• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec11
Ultragenyx CFO Reports Sale of Company Shares
17:12
Nov16
Ultragenyx Secures $400 Million Non-Dilutive Financing and Expands Crysvita Royalties
22:02
Nov5
Morgan Stanley Reiterates Buy Rating on Ultragenyx Pharmaceutical
17:21
Werber Reiterates Hold Rating on Ultragenyx Pharmaceutical
12:02
Ultragenyx Pharma released FY2025 Q3 earnings on November 4 After-Market EST, actual revenue USD 159.93 M (forecast USD 166.79 M), actual EPS USD -1.81 (forecast USD -1.2377)
00:00
Ultragenyx Pharma released FY2025 9 Months Earnings on November 4 After-Market EST, with actual revenue of USD 465.72 M and EPS of USD -4.5447
00:00

Schedules & Filings

Schedules
Filings
Nov4
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 159.93 M, Net Income -180.41 M, EPS -1.8082

Aug5
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 166.5 M, Net Income -114.95 M, EPS -1.1674

May6
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 139.29 M, Net Income -151.08 M, EPS -1.569

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
PCSA
6.750
+124.63%
+3.745
YCBD
2.386
+66.82%
+0.959
ATPC
0.1455
+61.67%
+0.056
VYNE
0.6041
+50.01%
+0.201
ISPO
4.190
+47.54%
+1.350
MGRT
7.353
+37.43%
+2.003
GVH
3.860
+30.85%
+0.910
ANDG
20.925
+30.78%
+4.925
MDLN
36.850
+27.07%
+7.850
DBVT
22.580
+25.58%
+4.600
View More